✦ LIBER ✦

First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma

✍ Scribed by Ralf Schmidmaier; Philipp Baumann; Irmgard Bumeder; Gerold Meinhardt; Christian Straka; Bertold Emmerich

Book ID: 114794233
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 506 KB
Volume: 79
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2007.00902.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib in recurrent and/or refractor

Bortezomib in recurrent and/or refractory multiple myeloma : Initial clinical experience in patients with impaired renal function

✍ Sundar Jagannath; Bart Barlogie; James R. Berenson; Seema Singhal; Raymond Alexa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

Clinical experience with thalidomide in

Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies

✍ Nikhil C Munshi; K.R Desikan; Bart Barlogie 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 649 KB

Overexpression of PDZK1 within the 1q12-

Overexpression of PDZK1 within the 1q12-q22 Amplicon Is Likely To Be Associated with Drug-Resistance Phenotype in Multiple Myeloma

✍ Jun Inoue; Takemi Otsuki; Akira Hirasawa; Issei Imoto; Yoshinobu Matsuo; Shiroh 📂 Article 📅 2004 🏛 American Society for Investigative Pathology 🌐 English ⚖ 845 KB

Upregulated expression of the PSMB5 gene

Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen

✍ Lü Shuqing; Yang Jianmin; Huang Chongmei; Cheng Hui; Jianmin Wang 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 111 KB

A phase III randomized study of oral ver

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study

✍ William S. Dalton; John J. Crowley; Sydney S. Salmon; Thomas M. Grogan; Leslie R 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 608 KB

Polymorphisms in the multiple drug resis

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

✍ Gabriele Buda; Deborah Ricci; C. Chris Huang; Reyna Favis; Nadine Cohen; Sen H. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 264 KB